Amy Ayers
YOU?
Author Swipe
View article: Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma
Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma Open
Introduction Though transformed indolent lymphomas (tiNHL) have historically been associated with poor outcomes in the relapsed or refractory (R/R) setting, novel treatments e.g. chimeric antigen receptor (CAR) T-cells offer some improveme…
View article: Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes
Prehabilitation prior to CAR T-cell therapy in non-Hodgkin lymphoma: Baseline physical function and toxicity outcomes Open
Background Emerging evidence suggests that baseline physical function may predict the toxicity of chimeric antigen receptor (CAR) T-cell therapy; however, there is no consensus on how best to evaluate physical function in this setting. The…
View article: Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study
Sequencing CD20-directed bispecific antibody and CD19-directed CAR T cell therapy in large B cell lymphoma: A multicenter real-world study Open
Introduction Multiple T-cell engaging therapies, including CD20-directed bispecific antibodies (BsAb) and CD19-directed chimeric antigen receptor T cell therapy (CAR T), are approved for use in relapsed and refractory (R/R) large B cell ly…
View article: Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy
Impact of extranodal sites of lymphoma on clinical outcomes after CD19 CAR T cell therapy Open
Background: Lymphomatous involvement of extranodal (EN) sites has been recognized as a negative prognostic factor for patients (pts) treated with chemoimmunotherapy and has been incorporated into risk stratification scores such as the IPI …
View article: PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy
PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy Open
Chronic lymphocytic leukemia (CLL) remains incurable despite treatment advances, and a major challenge is that biomarkers that predict response and resistance to current therapies are lacking. We report that activated and proliferating mal…
View article: 339 | OUTCOMES IN AN INTERNATIONAL MULTICENTRE STUDY OF 600 PATIENTS WITH CNS RELAPSE OF LARGE B CELL LYMPHOMA: COMPARTMENT OF RELAPSE IS PROGNOSTIC
339 | OUTCOMES IN AN INTERNATIONAL MULTICENTRE STUDY OF 600 PATIENTS WITH CNS RELAPSE OF LARGE B CELL LYMPHOMA: COMPARTMENT OF RELAPSE IS PROGNOSTIC Open
View article: 161 | OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM
161 | OUTCOMES OF GLOFITAMAB AND EPCORITAMAB IN R/R DLBCL ELDERLY PATIENTS: A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM Open
View article: 566 | REAL‐WORLD OUTCOMES OF MOSUNETUZUMAB USE FROM THE CUBIC CONSORTIUM
566 | REAL‐WORLD OUTCOMES OF MOSUNETUZUMAB USE FROM THE CUBIC CONSORTIUM Open
View article: 243 | REAL‐WORLD OUTCOMES OF CD20xCD3 BISPECIFIC ANTIBODY THERAPY IN ADULT PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED INDOLENT LYMPHOMA
243 | REAL‐WORLD OUTCOMES OF CD20xCD3 BISPECIFIC ANTIBODY THERAPY IN ADULT PATIENTS WITH RELAPSED/REFRACTORY TRANSFORMED INDOLENT LYMPHOMA Open
View article: 457 | BREATH BIOMARKERS FOR PREDICTION OF CYTOKINE RELEASE SYNDROME IN PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY
457 | BREATH BIOMARKERS FOR PREDICTION OF CYTOKINE RELEASE SYNDROME IN PATIENTS RECEIVING CHIMERIC ANTIGEN RECEPTOR T‐CELL THERAPY Open
View article: 671 | GLOFITAMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM
671 | GLOFITAMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, A REAL‐WORLD EVIDENCE STUDY FROM THE CUBIC CONSORTIUM Open
View article: 667 | REAL‐WORLD SAFETY AND EFFICACY OF EPCORITAMAB FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAS
667 | REAL‐WORLD SAFETY AND EFFICACY OF EPCORITAMAB FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMAS Open
View article: 456 | IDENTIFICATION OF AN OPTIMAL ABSOLUTE LYMPHOCYTE COUNT BEFORE LEUKAPHERESIS IN LARGE B‐CELL LYMPHOMA PATIENTS TREATED WITH CART
456 | IDENTIFICATION OF AN OPTIMAL ABSOLUTE LYMPHOCYTE COUNT BEFORE LEUKAPHERESIS IN LARGE B‐CELL LYMPHOMA PATIENTS TREATED WITH CART Open
View article: Outcomes of <scp>CD19 CAR</scp> T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma
Outcomes of <span>CD19 CAR</span> T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B‐Cell Lymphoma Open
Chimeric antigen receptor (CAR) T‐cell therapy has revolutionized treatment of aggressive large B‐cell lymphoma (aLBCL). Patients with transformed indolent non‐Hodgkin lymphoma (tiNHL) were included in key CAR trials, but outcomes of CAR f…
View article: Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma Open
Patients with r/r LBCL have unfavorable outcomes and need more effective treatment alternatives.
View article: 1443 Perception and factors influencing clinical trial participation among racial/ethnic minority breast and colorectal cancer patients
1443 Perception and factors influencing clinical trial participation among racial/ethnic minority breast and colorectal cancer patients Open
View article: Defining primary refractory large B-cell lymphoma
Defining primary refractory large B-cell lymphoma Open
Patients with large B-cell lymphoma (LBCL) that fail to achieve a complete response (CR) or who relapse early after anthracycline-containing immunochemotherapy (IC) have a poor prognosis and are commonly considered to have “primary refract…
View article: Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL
Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL Open
Prior studies have demonstrated that certain populations including older patients, racial/ethnic minority groups, and women are underrepresented in clinical trials. We performed a retrospective analysis of patients with non-Hodgkin lymphom…
View article: The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes
The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes Open
To address the current and long‐term unmet health needs of the growing population of non‐Hodgkin lymphoma (NHL) patients, we established the Lymphoma Epidemiology of Outcomes (LEO) cohort study (NCT02736357; https://leocohort.org/ ). A tot…
View article: Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients with Relapsed/Refractory Aggressive Large B-Cell Lymphoma
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients with Relapsed/Refractory Aggressive Large B-Cell Lymphoma Open
View article: Real‐world analysis of safety and efficacy of <scp>CAR</scp> T‐cell therapy in lymphoma patients with decreased kidney function
Real‐world analysis of safety and efficacy of <span>CAR</span> T‐cell therapy in lymphoma patients with decreased kidney function Open
To the Editor, Eligibility criteria for clinical trials, including CD19 chimeric antigen receptor T-cell (CAR-T) therapy trials, require patients to have adequate major organ function, and with respect to kidney function, this is defined a…
View article: ROLE OF PULMONARY FUNCTION TESTS TO PREDICT RESPIRATORY AND NON-RESPIRATORY COMPLICATIONS AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
ROLE OF PULMONARY FUNCTION TESTS TO PREDICT RESPIRATORY AND NON-RESPIRATORY COMPLICATIONS AFTER CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY Open
View article: POSTER: ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
POSTER: ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy Open
View article: ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy
ABCL-612 Real-World Outcomes in Patients With Relapsed or Refractory (r/r) Aggressive Large B-Cell Lymphoma (LBCL) Treated With Chemo-Immunotherapy Open
View article: Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes
Defining Primary Refractory Diffuse Large B‐cell Lymphoma (DLBCL) Based on Survival Outcomes Open
Background: DLBCL that fails to achieve a complete response (CR) or relapses early after standard immunochemotherapy (IC, e.g., R-CHOP or similar) is referred to as primary refractory DLBCL (prDLBCL) and has a poor prognosis. Different def…
View article: Supplementary Figure SF1 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF1 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 1. Anti-nucleocapsid IgG and spike IgM titers in NHL/CLL patients.
View article: Supplementary Figure SF5 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF5 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 5. Reduced IgG binding titers against the spike protein of SARS-CoV-2 variants in NHL/CLL patients.
View article: Supplementary Figure SF5 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF5 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 5. Reduced IgG binding titers against the spike protein of SARS-CoV-2 variants in NHL/CLL patients.
View article: Supplementary Figure SF3 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Supplementary Figure SF3 from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Supplemental Figure 3. Kinetics of serologic response after booster vaccination.
View article: Data from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
Data from Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies Open
Patients with non–Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM r…